Holen Sie sich die Stockscreener-App
56.79
0.14%
0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.71
Offen:
$56.64
24-Stunden-Volumen:
1.87M
Relative Volume:
0.83
Marktkapitalisierung:
$8.90B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
60.41
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
+3.50%
1M Leistung:
-3.39%
6M Leistung:
-11.47%
1J Leistung:
-20.40%
1-Tages-Spanne:
$56.10
$57.60
1-Wochen-Bereich:
$53.89
$57.60
52-Wochen-Spanne:
$46.01
$80.95
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
56.79 | 8.35B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Leading Biotech Company Bio-Techne Set for Three Major Wall Street Healthcare Conference Presentations - Stock Titan
Is Bio Techne Corporation a candidate for recovery playWeekly Trade Summary & Low Drawdown Investment Strategies - Newser
Applying big data sentiment scoring on Bio Techne CorporationProduct Launch & Daily Profit Maximizing Tips - Newser
Published on: 2025-08-26 12:53:37 - Newser
Using Ichimoku Cloud for Bio Techne Corporation technicalsQuarterly Trade Review & Stock Market Timing Techniques - Newser
Advanced analytics toolkit walkthrough for Bio Techne CorporationWeekly Loss Report & Precise Swing Trade Entry Alerts - Newser
Using Python tools to backtest Bio Techne Corporation strategiesRate Cut & Weekly High Potential Stock Alerts - Newser
Tools to monitor Bio Techne Corporation recovery probability2025 Short Interest & High Accuracy Trade Signal Alerts - Newser
Using economic indicators to assess Bio Techne Corporation potentialEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Is it time to cut losses on Bio Techne CorporationJuly 2025 Macro Moves & Reliable Price Breakout Signals - Newser
Applying sector rotation models to Bio Techne Corporation2025 Earnings Surprises & Safe Entry Point Alerts - Newser
Hong Kong biopharma stocks pull back; Ocumension Bio falls over 15% - AInvest
What machine learning models say about Bio Techne CorporationPortfolio Value Summary & AI Forecasted Entry and Exit Points - Newser
Bio-Techne Faces NIH & Tariff Uncertainty–Can They Outpace Policy Risks? - Smartkarma
Intraday pattern recognizer results for Bio Techne Corporation2025 Growth vs Value & Weekly Market Pulse Updates - Newser
What momentum shifts mean for Bio Techne CorporationNew Guidance & Community Trade Idea Sharing - Newser
Using flow based indicators on Bio Techne CorporationJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Published on: 2025-08-22 19:42:51 - 더경남뉴스
Bio-Techne Upgrade Amid Sector Challenges: Strong Q2 Performance and Easing Tariffs in China - AInvest
BIO-TECHNE Corp SEC 10-K Report - TradingView
Citi Upgrades Bio-Techne to Buy from Neutral with $70 Price Target - AInvest
Citigroup upgrades Bio-Techne to Buy with a new PT of $70. - AInvest
Understanding Bio Techne Corporation’s price movementQuarterly Profit Summary & Safe Investment Capital Preservation Plans - Newser
Bio Techne Corporation Stock Flags Risk Zone in Volatility Index2025 Pullback Review & Momentum Based Trading Signals - 더경남뉴스
Bio-Techne Stock: Analyst Estimates & Ratings - Barchart.com
How Bio Techne Corporation stock performs during market volatilityTrade Entry Report & Community Trade Idea Sharing - beatles.ru
What makes Bio Techne Corporation stock price move sharplyJuly 2025 Earnings & Expert Approved Momentum Ideas - 더경남뉴스
Stock Analysis | Bio-Techne OutlookA Stock to Watch with Mixed Signals - AInvest
Bio-Techne: Key Dividend Information and Recent Developments Ahead of Ex-Dividend Date on Aug 18, 2025 - AInvest
Three Companies Trading Ex-Dividend on 8/18/25 - AInvest
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and CNA Financial - Nasdaq
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates - GlobeNewswire Inc.
Bio-Techne's (NASDAQ:TECH) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know - Yahoo Finance
Bio-Techne Corporation shares rise 2.40% intraday as S&P 500, Nasdaq futures hit record highs. - AInvest
Bio-Techne's Q4 2025: Navigating Contradictions in NIH Funding, China Growth, and Revenue Outlook - AInvest
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call - Yahoo Finance
Stock Market Rally: Revvity, Avantor, Azenta, Bio-Techne, Amneal Shares Surge Amid Fed Interest Rate Cut Hopes - AInvest
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - Yahoo Finance
TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty - Yahoo Finance
Bio-Techne Earnings: Fourth-Quarter Results In-Line, but Volatile US Policy Is Hurting End Markets - Morningstar
Bio-Techne Leads Key Proteomic Reagent Markets, but Near-Term Challenges Loom - Morningstar
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls - MSN
Can Bio Techne Corporation disrupt its industryMaximum Leverage Stock Strategy - thegnnews.com
Bio-Techne Corp Q4 Earnings: Revenue Exceeds Estimates at $317M, Adjusted EPS Rises to $0.53, GAAP EPS Misses - AInvest
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $53 to $75 - 富途牛牛
Stocks making big moves yesterday: Bloomin' Brands, Bio-Techne, Snap, Grocery Outlet, and Paramount - Yahoo Finance
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $59 to $65 - 富途牛牛
Bio-Techne Corporation (NASDAQ:TECH) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Full Year 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Bio-Techne Exceeds Forecasts And Refines Its Focus On Growth - Finimize
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):